Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
424 Views
Emedinexus 08 June 2025
The FDA has approved Lumisight (pegulicianine) for use in breast cancer lumpectomies to help detect residual cancerous tissue. Given via IV before surgery, this fluorescent imaging drug enables surgeons to better identify and remove remaining cancer cells, potentially reducing the need for follow-up procedures.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}